The inclusion of a low-cost and “good enough” immunohistochemical test, based on the expression analysis of the cancer marker Galectin-3 in the decision-making strategy, instead of the expensive molecular testing, would be more cost-effective in especially, but not limited to, middle or low-income countries. This evidence concerns the gene LGALS3 and cancer.